These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38664179)

  • 1. Voided urine cytology is a useful tool predicting non-muscle-invasive bladder cancer risk before surgery.
    Gómez Del Cañizo C; González Ginel I; Martín-Arriscado Arroba C; de la Calle Moreno A; Hernández Arroyo M; Rodríguez Antolín A; Guerrero Ramos F
    Urol Oncol; 2024 Aug; 42(8):246.e15-246.e21. PubMed ID: 38664179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
    Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
    BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors.
    Smrkolj T; Cegovnik Primozic U; Fabjan T; Sterpin S; Osredkar J
    Radiol Oncol; 2020 Dec; 55(2):196-202. PubMed ID: 33764701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.
    Eissa S; Labib RA; Mourad MS; Kamel K; El-Ahmady O
    Eur Urol; 2003 Dec; 44(6):687-94. PubMed ID: 14644121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of positive urine cytology on progression and cancer-specific mortality of non--muscle-invasive bladder cancer.
    Koga F; Kobayashi S; Fujii Y; Ishioka J; Yokoyama M; Nakanishi Y; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
    Clin Genitourin Cancer; 2014 Jun; 12(3):e87-93. PubMed ID: 24169493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
    Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
    BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Mitropoulos D; Botsoli-Stergiou E; Constantinides C; Giannopoulou M; Choremi-Papadopoulou H
    Urology; 2000 Jun; 55(6):871-5. PubMed ID: 10840098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer.
    Eissa S; Zohny SF; Swellam M; Mahmoud MH; El-Zayat TM; Salem AM
    Clin Biochem; 2008 Nov; 41(16-17):1335-41. PubMed ID: 18804101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer.
    Erdmann K; Salomo K; Klimova A; Heberling U; Lohse-Fischer A; Fuehrer R; Thomas C; Roeder I; Froehner M; Wirth MP; Fuessel S
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of urinary molecular markers in bladder cancer.
    Eissa S; Swellam M; el-Mosallamy H; Mourad MS; Hamdy NΜ; Kamel K; Zaglol AS; Khafagy MM; el-Ahmady O
    Anticancer Res; 2003; 23(5b):4347-55. PubMed ID: 14666650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
    Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Bard BTA test: its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer.
    Schamhart DH; de Reijke TM; van der Poel HG; Witjes JA; de Boer EC; Kurth K; Schalken JA
    Eur Urol; 1998 Aug; 34(2):99-106. PubMed ID: 9693243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BTA test is superior to voided urine cytology in detecting malignant bladder tumours.
    Heino A; Aaltomaa S; Ala-Opas M
    Ann Chir Gynaecol; 1999; 88(4):304-7. PubMed ID: 10661829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can sensitivity of voided urinary cytology or bladder wash cytology be improved by the use of different urinary portions?
    Mungan NA; Kulacoglu S; Basar M; Sahin M; Witjes JA
    Urol Int; 1999; 62(4):209-12. PubMed ID: 10567884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
    Raitanen MP; Aine RA; Kaasinen ES; Liukkonen TJ; Kylmälä TM; Huhtala H; Tammela TL;
    Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
    Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
    Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
    Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
    BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of the BTA test in bladder cancer: a multicenter trial. BTA Study Group Japan.
    Miyanaga N; Akaza H; Kameyama S; Hachiya T; Ozono S; Kuroda M; Koga H; Koiso K
    Int J Urol; 1997 Nov; 4(6):557-60. PubMed ID: 9477183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Bard Trak test with voided urine cytology in the diagnosis and follow-up of bladder tumors.
    Chautard D; Daver A; Bocquillon V; Verriele V; Colls P; Bertrand G; Soret JY
    Eur Urol; 2000 Dec; 38(6):686-90. PubMed ID: 11111185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.